Medical Technology and Devices (MTD) is pleased to announce the successful completion of the strategic acquisition of Ypsomed’s pen needles and blood glucose monitoring systems (BGM) business units, announced at the end of March. This acquisition is an important step in MTD’s mission to provide world-class solutions for the treatment of diabetes and obesity on a global scale.
Strengthening our position as number 2 in the world by increasing production capacity to over 2.5 billion pen needles
With this acquisition, MTD strengthens its position as the clear number two in the global market for pen needles. This strategic acquisition not only solidifies our leadership position in diabetes care, but also underscores our commitment to delivering innovative solutions for both self-care and professional use. We will integrate Ypsomed’s pen needles into our European production and sales network, increasing our total production capacity to over 2.5 billion pen needles.
An exclusive portfolio designed to provide comprehensive coverage to more patients, consumers and healthcare professionals
The integration of Ypsomed’s businesses brings a wealth of advanced technologies and brands to MTD’s diabetes and obesity portfolio and complements our current product offering, which includes the G34, the thinnest and shortest pen needle on the market. Strengthens with this acquisition MTD maintains its unique positioning by being able to offer a complete range of 3, 5 and 6 grind pen needles, click technology for an easy and secure fit, as well as single and double protection in safety pen needles. In addition, we recently launched continuous blood glucose monitoring (CGM) systems, winning tenders in Italy, marking our entry into this segment this year. This exclusive portfolio for diabetes care underlines our ongoing commitment to innovation in professional and private healthcare. It includes sharp medical instruments such as the blood collection safety needle, veterinary catheter and the new passive safety needle, Pic Protecto. In addition, new blood pressure monitors, inhalers, foot care products and insect repellents will be launched in 2024.
Reaching 3 billion new consumers by entering the Chinese and Indian markets
The acquisition enables entry into strategic, high-growth markets such as China and India while strengthening our presence in established markets such as North America, Germany and France. This expansion is a critical step for MTD as we look to further expand our global reach and influence in the diabetes industry.
Investment in a state-of-the-art production facility
As part of its strategy of growth and continuous improvement, MTD is implementing a major investment plan to create the most competitive pen needle and lancet manufacturing facilities in Europe. These investments aim to increase capacity and further improve the performance, quality and ESG performance of our manufacturing operations.
“The completion of this acquisition is a pivotal moment for MTD Group. By integrating Ypsomed’s pen needles and blood glucose meters business areas, we are consolidating our position as the world’s leading provider of diabetes care and establishing ourselves as the second largest manufacturer of pen needles worldwide. This strategic move strengthens our ability to deliver innovative, high-quality solutions to our customers and expands our reach in key markets. Our significant investments underline our commitment to efficiently scaling our operations while maintaining the highest quality standards. We are excited about the opportunities this acquisition presents and remain committed to advancing the future of diabetes care,” wise Charles Bouaziz, CEO of MTD Group.
MTD was supported by Studio Legale LCA for the legal aspects, with Roberto de Bonis, Sara Consoli and Mario Niggeler acting.
Information about MTD Group
“Enable everyone to be in control of their health, from start to finish, through intuitive monitoring, painless medication delivery, and easy-to-use solutions to everyday aches and pains.”
Medical Technology and Devices (MTD) is a consumer health group with a portfolio of global brands leading in diabetes, medical sharps, wound care, cardiac monitors, thermometers and nebulizers. MTD owns Pic Solution in EMEA/APAC and Droplet in North America, iconic brands with more than 40 years of history and 90% consumer recognition. The product portfolio is distributed in more than 100 markets – reaching half of the world’s population – thanks to direct branches in Italy, the USA, France, Germany and India, as well as through a long-standing dealer network in the rest of the world. MTD has an extensive research and development department that develops and researches the most innovative technologies to meet the rapidly changing needs of consumers and healthcare professionals. Production takes place in a state-of-the-art production system with 4 production sites across Europe. The Group was created in 2018 from the merger of Pikdare and HTL Strefa and is based in Milan, Italy. The company is led by an international management team and has around 1,400 employees.
Logo: https://mma.prnewswire.com/media/2469174/4829787/MTD_Logo.jpg
